Reductions in Frontocortical Cytokine Levels are Associated with Long-Lasting Alterations in Reward Valuation after Methamphetamine

Neuropsychopharmacology

Volumn 40, Issue , 2015, Pages 1234-1242

  Stolyarova, Alexandra ^a   Thompson, Andrew B ^a   Barrientos, Ruth M ^b   Izquierdo, Alicia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHAMPHETAMINE; TUMOR NECROSIS FACTOR ALPHA; CENTRAL STIMULANT AGENT;

ADULT; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; MALE; MAZE TEST; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; REWARD; BRAIN REGION; DISSECTION; DRUG EFFECT; DRUG EXPOSURE; HABITUATION; TASK PERFORMANCE; AMYGDALA; ANIMAL; DECISION MAKING; DRUG EFFECTS; FRONTAL LOBE; IMMUNOLOGY; IMMUNOMODULATION; LONG EVANS RAT; METABOLISM; MOTIVATION; PHYSIOLOGY;

AMYGDALA; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOICE BEHAVIOR; CYTOKINES; FRONTAL LOBE; MALE; MAZE LEARNING; METHAMPHETAMINE; MOTIVATION; NEUROIMMUNOMODULATION; RATS, LONG-EVANS; REWARD;

EID: 84925498621     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.309     Document Type: Article

References (54)

1. Adlaf EM, Smart RG (1983). Risk-taking and drug-use behavior: an examination. Drug Alcohol Depend 11: 287-296.
2. Akindipe T, Wilson D, Stein DJ (2014). Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab Brain Dis 29: 351-357.
3. Barrientos RM, Frank MG, Hein AM, Higgins EA, Watkins LR, Rudy JW et al (2009). Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection. Brain Behav Immun 23: 46-54.
4. Beitner-Johnson D, Guitart X, Nestler EJ (1993). Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area. J Neurochem 61: 1766-1773.
5. Bickel WK, Marsch LA (2001). Toward a behavioral economic understanding of drug dependence: delay discounting processes. Addiction 96: 73-86.
6. Bickel WK, Jarmolowicz DP, Mueller ET, Gatchalian KM (2011). The behavioral economics and neuroeconomics of reinforcer pathologies: implications for etiology and treatment of addiction. Curr Psychiatry Rep 13: 406-415.
7. Blair K, Marsh AA, Morton J, Vythilingam M, Jones M, Mondillo K et al (2006). Choosing the lesser of two evils, the better of two goods: specifying the roles of ventromedial prefrontal cortex and dorsal anterior cingulate in object choice. J Neurosci 26: 11379-11386.
8. Cadet J, Bisagno V (2014). Glial-neuronal ensembles: partners in drug addiction-associated synaptic plasticity. Front Pharmacol 5: 204.
9. Carroll ME, Lac ST, Nygaard SL (1989). A concurrently available nondrug reinforcer prevents the acquisition or decreases the maintenance of cocaine-reinforced behavior. Psychopharmacology (Berl) 97: 23-29.
10. Chau BK, Kolling N, Hunt LT, Walton ME, Rushworth MF (2014). A neural mechanism underlying failure of optimal choice with multiple alternatives. Nat Neurosci 17: 463-470.
11. Clark KH, Wiley CA, Bradberry CW (2013). Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res 23: 174-188.
12. Coller JK, Hutchinson MR (2012). Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacol Ther 134: 219-245.
13. Csontos C, Foldi V, Palinkas L, Bogar L, Roth E, Weber G et al (2010). Time course of pro- and anti-inflammatory cytokine levels in patients with burns-prognostic value of interleukin-10. Burns 36: 483-494.
14. Darke S, Kaye S, McKetin R, Duflou J (2008). Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27: 253-262.
15. De Martino B, Kumaran D, Seymour B, Dolan RJ (2006). Frames, biases, and rational decision-making in the human brain. Science 313: 684-687.
16. Diekhof EK, Falkai P, Gruber O (2008). Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders. Brain Res Rev 59: 164-184.
17. Dezfouli A, Piray P, Keramati MM, Ekhtiari H, Lucas C, Mokri AA (2009). Neurocomputational model for cocaine addiction. Neural Comput 21: 2869-2893.
18. Featherstone RE, Rizos Z, Kapur S, Fletcher PJ (2008). A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. Behav Brain Res 189: 170-179.
19. Fletcher PJ, Tenn CC, Sinyard J, Rizos Z, Kapur S (2007). A sensitizing regimen of amphetamine impairs visual attention in the 5-choice serial reaction time test: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Neuropsychopharmacology 32: 1122-1132.
20. Flora G, Lee YW, Nath A, Maragos W, Hennig B, Toborek M (2002). Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Med 2: 71-85.
21. Floresco SB, Whelan JM (2009). Perturbations in different forms of cost/benefit decision making induced by repeated amphetamine exposure. Psychopharmacology (Berl) 205: 189-201.
22. Gonc¸alves J, Martins T, Ferreira R, Milhazes N, Borges F, Ribeiro CF et al (2008). Methamphetamine-induced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain. Ann N Y Acad Sci 1139: 103-111.
23. Goshen I, Kreisel T, Ounallah-Saad H, Renbaum P, Zalzstein Y, Ben-Hur T et al (2007). A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 32: 1106-1115.
24. Henry CJ, Huang Y, Wynne AM, Godbout JP (2009). Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun 23: 309-317.
25. Hoffman WF, Moore M, Templin R, McFarland B, Hitzemann RJ, Mitchell SH (2006). Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology (Berl) 188: 162-170.
26. Horowitz JK, List J, McConnell KE (2007). A test of diminishing marginal value. Economica 74: 650-663.
27. Hutchinson MR, Watkins LR (2014). Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacology 76: 218-227.
28. Hyman SE, Malenka RC, Nestler EJ (2006). Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29: 565-598.
29. Izquierdo A, Murray EA (2007). Selective bilateral amygdala lesions in rhesus monkeys fail to disrupt object reversal learning. J Neurosci 27: 1054-1062.
30. Kamm K, Vanderkolk W, Lawrence C, Jonker M, Davis AT (2006). The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J Trauma 60: 152-157.
31. Kitanaka J, Kitanaka N, Takemura M (2008). Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: a review. Neurochem Res 33: 204-219.
32. Kosheleff AR, Grimes M, O'Dell SJ, Marshall JF, Izquierdo A (2011). Work aversion and associated changes in dopamine and serotonin transporter after methamphetamine exposure in rats. Psychopharmacology (Berl) 219: 411-420.
33. Kosheleff AR, Rodriguez D, O'Dell SJ, Marshall JF, Izquierdo A (2012). Comparison of single-dose and escalating methamphetamine administration on reversal learning in rats. Psychopharmacology (Berl) 224: 459-467.
34. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS (2005). Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8: 1450-1457.
35. Larson SJ, Romanoff RL, Dunn AJ, Glowa JR (2002). Effects of interleukin-1beta on food-maintained behavior in the mouse. Brain Behav Immun 16: 398-410.
36. Loftis JM, Choi D, Hoffman W, Huckans MS (2011). Methamphetamine causes persistent immune dysregulation: a cross-species, translational report. Neurotox Res 20: 59-68.
37. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J et al (2004). Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61: 73-84.
38. Mackillop J, Amlung MT, Few LR, Ray LA, Sweet LH, Munafo MR (2011). Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacology (Berl) 216: 305-321.
39. Miller AH, Haroon E, Raison CL, Felger JC (2013). Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 30: 297-306.
40. Monterosso JR, Ainslie G, Xu J, Cordova X, Domier CP, London ED (2007). Frontoparietal cortical activity of methamphetamine-dependent and comparison subjects performing a delay discounting task. Hum Brain Mapp 28: 383-393.
41. Narita M, Miyatake M, Narita M, Shibasaki M, Shindo K, Nakamura A et al (2006). Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 31: 2476-2488.
42. Narita M, Miyatake M, Shibasaki M, Tsuda M, Koizumi S, Narita M et al (2005). Long-lasting change in brain dynamics induced by methamphetamine: enhancement of protein kinase C-dependent astrocytic response and behavioral sensitization. J Neurochem 93: 1383-1392.
43. Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA et al (2014). Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/chow feeding choice task. Psychopharmacology (Berl) 231: 727-736.
44. Pometlová M, Nohejlová-Deykun K, Šlamberová R (2012). Anxiogenic effect of low-dose methamphetamine in the test of elevated plus-maze. Prague Med Rep 113: 223-230.
45. Reutskaja E, Hogarth RM (2009). Satisfaction in choice as a function of the number of alternatives: when "goods satiate". Psychol Mark 26: 197-203.
46. Roesch MR, Calu DJ, Schoenbaum G (2007). Dopamine neurons encode the better option in rats deciding between differently delayed or sized rewards. Nat Neurosci 10: 1615-1624.
47. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K et al (2008). Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28: 5756-5761.
48. Shafiei N, Gray M, Viau V, Floresco SB (2012). Acute stress induces selective alterations in cost/benefit decision-making. Neuropsychopharmacology 37: 2194-2209.
49. Song C, Horrobin DF, Leonard BE (2006). The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats. Pharmacopsychiatry 39: 88-99.
50. Stellwagen D, Beattie EC, Seo JY, Malenka RC (2005). Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 25: 3219-3228.
51. Stolyarova A, O'Dell SJ, Marshall JF, Izquierdo A (2014). Positive and negative feedback learning and associated dopamine and serotonin transporter binding after methamphetamine. Behav Brain Res 271: 195-202.
52. Thijs LG, Hack CE (1995). Time course of cytokine levels in sepsis. Intensive Care Med 21(Suppl 2): S258-S263.
53. Turrin NP, Gayle D, Ilyin SE, Flynn MC, Langhans W, Schwartz GJ et al (2001). Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res Bull 54: 443-453.
54. Vichaya EG, Hunt SC, Dantzer R (2014). Lipopolysaccharide reduces incentive motivation while boosting preference for high reward in mice. Neuropsychopharmacology 39: 2884-2890.